Correlated Drug Terms (0)

---

	Name (Synonyms)	Correlation

Correlated MeSH Terms (1)

---

	Name (Synonyms)	Correlation
D003924	Diabetes Mellitus, Type 2 NIH	0.32

Correlated HPO Terms (1)

---

	Name (Synonyms)	Correlation
HP:0005978	Type II diabetes mellitus HPO	0.32

Primary Outcomes

Description: Recruitment levels will be defined as the number of people signed up over number of eligible people approached at intake and in class, presented as a percentage of sign up rates.

Measure: Feasibility: Recruitment

Time: from the date of of the first participant recruited the last participant recruited for the study (estimated last date for recruitment cut off is November 14th, 2020; allowing for study data collection completion by December 18, 2020).

---

Description: Retention will be calculated as number of participants completed post-intervention follow-up assessment divided by initial sample size.

Measure: Feasibility: Retention

Time: From time of consent and up to 9 weeks later (study completion)

---

Description: Acceptability will be assessed from participant feedback from the exit survey. Acceptability data gathered from the exit survey will be analyzed in a qualitative or descriptive fashion, using frequencies and means (i.e. "this many rated the lottery draw as a motivation to get them to attend class as "strongly agree": 93%"). Technical difficulties will be dealt with (by contact) and recorded by the Master's student in the STAND-VAT activity log. Number of reported technology issues will be reported as a total in addition to average mean # of technology issues per person. Counting will be used based on type of issue using categories like: a) lost/disrupted internet connection or unable to connect or hear or see during class; b) issues utilizing FitBit/FitBit app c) Issues with uploading FitBit data; d) other. Difficulty assessment will provide insight for improvements for larger future studies.

Measure: Feasibility: Acceptability

Time: Week 1 of intervention up to time of follow up (7 weeks later)

---

Description: Adherence will be assessed by the percent of biweekly classes attended and check-in phone calls answered, as well as number of data submissions (all out of three).

Measure: Feasibility: Adherence

Time: Week 1 of intervention to week 6

---

Secondary Outcomes

Description: The change in daily step counts will be measured using repeated, average daily step counts each week collected by the FitBit Inspire HR© during baseline, W1-W6. The mean number of change in daily step counts will be reported.

Measure: Participant Behaviour; Exercise Behaviours: Daily Step Count

Time: 1-week Baseline to end of week 6 of intervention (total 7 weeks assessed)

---

Description: The hourly move goals are used to break and reduce sedentary behaviour. Change in sedentary time will be measured using repeated weekly average daily sedentary minutes collected by the FitBit Inspire HR©, during baseline, W1-W6.

Measure: Participant Behaviour; Exercise Behaviours: Daily Sedentary Time

Time: 1-week Baseline to end of week 6 of intervention (total 7 weeks assessed)

---

Description: Adherence to the exercise prescription will be measured by the total number of daily step goals achieved divided by number of days participated throughout the six weeks. The step goals completion numbers demonstrate intervention acceptability and will allow for further reflection on the achievability and appropriate progression rate of the exercise prescriptions. This will be presented as a percentage, calculated by number of days with step goals achieved over total number of days of the program.

Measure: Participant Behaviour; Exercise Behaviours: Exercise Prescription Adherence

Time: week 1 to week 6 of intervention

---

Description: Weekly average daily time in glycemic target will be repeatedly measured from the first week of the intervention week one (W1) (when the first FreeStyle Libre is applied) and each week until W6.

Measure: Glycemic Control Measures: Time in Glycemic Target

Time: Weekly assessment from week 1 to week 6 of intervention

---

Description: At the clinic, A1c levels are routinely collected every three months. However, since this is a six-week study, A1c will be measured using the weekly average estimated A1c reading from Week 1 (when the first FreeStyle Libre is applied) and each week until week 6.

Measure: Glycemic Control Measures: Estimated A1c

Time: Weekly assessment from week 1 to week 6 of intervention

---

Description: Functional fitness levels will be assessed using the two-minute step test. The two minute step test is a two minute, sub maximal test requiring participants to step on the spot, brining knees to mid-thigh level. Scoring is based on number of times the right knee rises within the two minutes.

Measure: Functional Fitness Levels

Time: At Baseline and at post-intervention follow-up (7 weeks later)

---

Description: Chronic disease self-efficacy will be measured using the Stanford Self-Efficacy Scale. The Stanford Self-Efficacy Scale is a reliable, validated six-item questionnaire that assesses the self-efficacy to manage a chronic disease, including exercise (Lorig et al., 2001; Ritter & Lorig, 2014). Scores range from 1 (not confident) to 10 (very confident). Higher scores mean higher self-efficacy.

Measure: Participant Attitudes: Chronic Disease Self-Efficacy

Time: At Baseline and at post-intervention follow-up (7 weeks later)

---

Description: Diabetes related emotional distress will be measured using the PAID-5. The five item Problem Areas in Diabetes Scale (PAID-5) is a valid and reliable short version of the PAID Scale, focusing on emotional distress scale (McGuire et al., 2010). Each question is ranked from zero (not a problem) to four (serious problem). A total score of eight or greater indicates possible emotional distress and may warrant further investigation.

Measure: Participant Attitudes: Diabetes Emotional Distress

Time: At Baseline and at post-intervention follow-up (7 weeks later)

---

HP:0005978: Type II diabetes mellitus

Genes 182

MKRN3-AS1 IGF2BP2 ABCC8 CNGA1 LIMK1 DHDDS RFC2 SLC2A2 AMACR PCNT EYS PDX1 KIZ MEN1 SPINK1 REEP6 RGR PRPF6 GTF2I XRCC4 KIAA1549 PRPF8 DHX38 LIG4 IDH3A ABCC8 ELN TRNF PTPN1 GUCA1B NEK2 PDE6G CTNNB1 CLCNKB SNRPN WFS1 PWAR1 MAK HMGA1 CLIP2 RHO BBS2 KCNJ11 ATM RP9 PPP1R3A DMXL2 PAX4 TOPORS TCF7L2 KLHL7 HNF1A IDH3B RDH12 ZNF408 SCAPER ABCA4 RLBP1 C8ORF37 BRAF AKT2 ND1 ND4 ARL2BP PLCD1 PDE6B GCK CERKL NRL COX1 TRNE HNF1A MTNR1B AIP TRNW NPAP1 MKRN3 TRNQ ND5 LMNA TRNK PROM1 NEUROD1 IRS2 PRPF3 USH2A RP2 SPATA7 MOG ND6 IMPDH1 BLM CYP19A1 IFT172 SLC7A14 ALMS1 PRCD SNORD116-1 CAT TRNL1 PNPLA6 FAM161A RPE65 FBN1 AGBL5 WRN PRPH2 ROM1 TBL2 COX3 PRPF4 PDX1 CA4 TUB CEP19 RPGR TTC8 SEMA4A POLR3A ARL3 BEST1 LRAT NR2E3 CRX TULP1 SNRNP200 IFT88 POLA1 PWRN1 NDN PCARE AR INSR FSCN2 RETN COX2 STUB1 MC4R ENPP1 MERTK RBP3 CNGB1 LIPC ZNF513 BAZ1B TRNS2 GPD2 PPARG AHI1 HGSNAT IMPG2 IFT140 POMGNT1 KLF11 IRS1 HNF4A IPW GCK SAG PRPF31 HNF1B HERC2 PEX10 GLRX5 OFD1 SLC30A8 ARHGEF18 TRNS1 MAGEL2 RP1 MAPK8IP1 ARL6 GTF2IRD1 TRNL1 CLRN1 AHR SLC12A3 TRNH PDE6A CDHR1 SNORD115-1 CRB1

Protein Mutations 12

A54T E158K E23K G174S G212A G401S G465R I349V K121Q P12A R230C R61C

SNP 9

rs10401969 rs13266634 rs2266782 rs2854275 rs35652124 rs780094 rs780094s rs78408340 rs7903146